TY  - JOUR
N1  - Copyright of this article belongs to MDPI
ID  - open2728
UR  - https://www.mdpi.com/2073-4409/10/8/1847
IS  - 8
A1  - Negi, Sushmita
A1  - Saini, Sheetal
A1  - Tandel, Nikunj
A1  - Sahu, Kiran
A1  - Mishra, Ravi P. N.
A1  - Tyagi, Rajeev K.
Y1  - 2021/07/21/
N2  - Crohn's disease and ulcerative colitis, two major forms of inflammatory bowel disease (IBD) in humans, afflicted in genetically predisposed individuals due to dysregulated immune response directed against constituents of gut flora. The defective immune responses mounted against the regulatory mechanisms amplify and maintain the IBD-induced mucosal inflammation. Therefore, restoring the balance between inflammatory and anti-inflammatory immunepathways in the gut may contribute to halting the IBD-associated tissue-damaging immune response. Phenotypic and functional characterization of various immune-suppressive T cells (regulatory T cells; Tregs) over the last decade has been used to optimize the procedures for in vitro expansion of these cells for developing therapeutic interventional strategies. In this paper, we review the mechanisms of action and functional importance of Tregs during the pathogenesis of IBD and modulating the disease induced inflammation as well as role of mouse models including humanized mice repopulated with the human immune system (HIS) to study the IBD. "Humanized" mouse models provide new tools to analyze human Treg ontogeny, immunobiology, and therapy and the role of Tregs in developing interventional strategies against IBD. Overall, humanized mouse models replicate the human conditions and prove a viable tool to study molecular functions of human Tregs to harness their therapeutic potential.
PB  - MDPI
JF  - CELLS
VL  - 10
KW  - humanized mice; inflammatory bowels disease; Crohn?s disease; ulcerative colitis; human immune system; regulatory T cells
TI  - Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice
ER  -